Projects per year
Personal profile
Education
Ph.D., National Yang Ming Chiao Tung University,Taiwan
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Wei Teng is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Active
-
Utilizing Multi-Omics Approach to Investigate the Association between Hbv Quasispecies and Host Antiviral Immune Phenotype Along with Their Impacts on Clinical Outcome and Treatment Efficacy
Jeng, W.-J. (PI), Huang, C. H. (CoPI), Lin, C.-Y. (CoPI), Lin, P. T. (CoPI), Teng, W. (CoPI) & Yang, H. I. (CoPI)
01/08/24 → 31/07/25
Project: National Science and Technology Council › National Science and Technology Council Academic Grants
-
An Investigation into the Role and Underlying Mechanisms of Innate-Like T Cells in Hcc Patients Receiving Immune Checkpoint Inhibitors by Single Cell Approach
Teng, W. (PI) & Lin, C.-Y. (CoPI)
01/08/24 → 31/07/25
Project: National Science and Technology Council › National Science and Technology Council Academic Grants
-
Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma
Su, C. W., Teng, W., Shen, E. Y. L., Huang, B. S., Lin, P. T., Hou, M. M., Wu, T. H., Tsan, D. L., Hsieh, C. H., Wang, C. T., Chai, P. M., Lin, C. Y., Lin, S. M. & Lin, C. C., 01 07 2024, In: Oncologist. 29, 7, p. e922-e931Research output: Contribution to journal › Journal Article › peer-review
Open Access -
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (Hepatology International, (2021), 15, 6, (1421-1430), 10.1007/s12072-021-10263-x)
Teng, W., Chang, T., Yang, H., Peng, C., Su, C., Su, T., Hu, T., Yu, M., Yang, H. & Wu, J., 06 2024, In: Hepatology International. 18, 3, p. 1066 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression
on behalf of Taiwan Liver Cancer Association Research Group (TRG), 2024, (Accepted/In press) In: Liver Cancer.Research output: Contribution to journal › Journal Article › peer-review
Open Access -
Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment
Lin, P. T., Teng, W., Jeng, W. J., Lin, C. C., Lin, C. Y., Lin, S. M. & Sheen, I. S., 07 2024, In: Journal of the Formosan Medical Association. 123, 7, p. 788-795 8 p.Research output: Contribution to journal › Journal Article › peer-review
Open Access1 Scopus citations -
Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients
Lin, P. T., Teng, W., Jeng, W. J., Lin, C. Y., Lin, S. M. & Sheen, I.-S., 01 02 2022, In: European Journal of Gastroenterology and Hepatology. 34, 2, p. 213-219 7 p.Research output: Contribution to journal › Journal Article › peer-review
10 Scopus citations